Q-omics provides the consensus-scored NKX6-3 profile across patient tissues and cancer cell-line models. NKX6-3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, NKX6-3 is differentially expressed in 7, with the highest sampling consensus in READ. Additionally, NKX6-3 RNA expression shows 9,326 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LGG, READ, and TGCT as cancer lineages where NKX6-3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NKX6-3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NKX6-3 survival associations across molecular data types. NKX6-3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NKX6-3 RNA expression–survival associations across cancer types. High NKX6-3 expression shows unfavorable associations in UVM, COAD, ACC and STAD, but favorable associations in LGG and ESCA. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for NKX6-3 RNA expression.
This table summarizes NKX6-3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in READ for RNA.
This table ranks reproducible tumor–normal expression differences for NKX6-3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NKX6-3 shows lower tumor expression in READ and higher tumor expression in LUAD, UCEC, LUSC, PRAD and KIRC. The READ box plot shows higher NKX6-3 RNA expression in normal versus tumor tissue (log2 FC = −0.130, t-test p = .006).
This table shows molecular features associated with NKX6-3 in patient tissues and cancer cell lines. In patient samples, NKX6-3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NKX6-3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
